1.3.1.48	13,14-dihydro-15-prostaglandin E2	competitive product inhibition	42975	
1.3.1.48	15-keto prostaglandin F2alpha	43.06% residual activity at 0.1 mM	68883	
1.3.1.48	5-(2-chloro-3-((4-methylcyclohexyl)methoxy)benzylidene)-1,3-thiazolidine-2,4-dione	-	224555	
1.3.1.48	5-(2-chloro-3-((5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)oxy)benzylidene)-1,3-thiazolidine-2,4-dione	-	224566	
1.3.1.48	5-(2-chloro-3-(1-cyclopropylethoxy)benzylidene)-1,3- thiazolidine-2,4-dione	-	224563	
1.3.1.48	5-(2-chloro-3-(2-(4-methyl-1,3-thiazolidin-5-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione	-	224557	
1.3.1.48	5-(2-chloro-3-(2-(cyclohexyloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione	-	224560	
1.3.1.48	5-(2-chloro-3-(2-(propan-2-yloxy)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione	-	224556	
1.3.1.48	5-(2-chloro-3-(2-(pyridin-2-yl)ethoxy)benzylidene)-1,3-thiazolidine-2,4-dione	-	217193	
1.3.1.48	5-(2-chloro-3-(2-cyclohexylethoxy)benzylidene)thiazolidine-2,4-dione	-	224574	
1.3.1.48	5-(2-chloro-3-(2-cyclopentylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione	-	224558	
1.3.1.48	5-(2-chloro-3-(3-cyclohexylpropoxy)benzylidene)thiazolidine-2,4-dione	-	224575	
1.3.1.48	5-(2-chloro-3-(3-nitrophenoxy)benzylidene)-1,3-thiazolidine-2,4-dione	-	224565	
1.3.1.48	5-(2-chloro-3-(3-phenylpropoxy)benzylidene)thiazolidine-2,4-dione	the compound significantly increases the level of PGE2 in skin defects	224570	
1.3.1.48	5-(2-chloro-3-(4-cyclohexylbutoxy)benzylidene)thiazolidine-2,4-dione	-	224576	
1.3.1.48	5-(2-chloro-3-(4-nitrobenzyloxy)benzylidene)thiazolidine-2,4-dione	-	224559	
1.3.1.48	5-(2-chloro-3-(4-phenylbutoxy)benzylidene)thiazolidine-2,4-dione	-	224571	
1.3.1.48	5-(2-chloro-3-(cyclobutylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione	-	224561	
1.3.1.48	5-(2-chloro-3-(cyclohexylmethoxy)benzylidene)thiazolidine-2,4-dione	-	224573	
1.3.1.48	5-(2-chloro-3-(cyclohexyloxy)benzylidene)thiazolidine-2,4-dione	-	224572	
1.3.1.48	5-(2-chloro-3-(cyclopentylmethoxy)benzylidene)-1,3-thiazolidine-2,4-dione	-	224562	
1.3.1.48	5-(2-chloro-3-(cyclopentyloxy)benzylidene)-1,3-thiazolidine-2,4-dione	-	224567	
1.3.1.48	5-(2-chloro-3-phenethoxybenzylidene)thiazolidine-2,4-dione	-	224569	
1.3.1.48	5-(3-(benzyloxy)-2-chlorobenzylidene)thiazolidine-2,4-dione	-	224568	
1.3.1.48	5-(3-(bicyclo[2.2.1]hept-2-ylmethoxy)-2-chlorobenzylidene)-1,3-thiazolidine-2,4-dione	-	224564	
1.3.1.48	benzylidene acetophenone	21.09% residual activity at 0.5 mM	68884	
1.3.1.48	Cibacron blue 3 G-A	competitive inhibition vs. NADH, noncompetitive vs. 15-keto-prostaglandin E2	43928	
1.3.1.48	Cibacron blue 3 G-A	-	43928	
1.3.1.48	ciglitazone	-	17605	
1.3.1.48	dicoumarol	0.1 mM, 86% inhibition, cofactor NADPH, substrate 15-ketoprostaglandin E2	754	
1.3.1.48	dicoumarol	0.1 mM, complete inhibition	754	
1.3.1.48	dicoumarol	11.45% residual activity at 0.1 mM	754	
1.3.1.48	Disulfiram	0.1 mM, 61% inhibition, cofactor NADPH, substrate 15-ketoprostaglandin E2	986	
1.3.1.48	indomethacin	0.1 mM, 97% inhibition, cofactor NADPH, substrate 15-ketoprostaglandin E2	546	
1.3.1.48	indomethacin	0.1 mM, 95% inhibition	546	
1.3.1.48	indomethacin	-	546	
1.3.1.48	indomethacin	14.22% residual activity at 0.1 mM	546	
1.3.1.48	additional information	finasteride has no inhibitory effect	2	
1.3.1.48	additional information	evaluation of non-steroidal anti-inflammatory drugs (NSAIDs) as enzyme potential inhibitors	2	
1.3.1.48	additional information	thiazolidinediones as enzyme inhibitors. No inhibition by 5-(2-chloro-3-(1-cyclopropylethoxy)benzylidene)-1,3-thiazolidine-2,4-dione	2	
1.3.1.48	NADH	uncompetitive inhibition at high concentrations	8	
1.3.1.48	NADP+	-	10	
1.3.1.48	NADPH	competitive inhibition vs. NADH, noncompetitive vs. 15-keto-prostaglandin E2	5	
1.3.1.48	NADPH	-	5	
1.3.1.48	p-chloromercuribenzoate	-	43	
1.3.1.48	p-chloromercuribenzoate	0.0001 mM, 85% inhibition	43	
1.3.1.48	p-chloromercuribenzoate	0.1 mM, complete inhibition	43	
1.3.1.48	p-chloromercuribenzoate	0.1 mM, 97% inhibition	43	
1.3.1.48	quercitrin	0.1 mM, 76% inhibition, cofactor NADPH, substrate 15-ketoprostaglandin E2	1936	
1.3.1.48	quercitrin	95% inhibition	1936	
1.3.1.48	quercitrin	13.14% residual activity at 0.1 mM	1936	
1.3.1.48	thiazolidinedione	-	18785